Adams Not Phlegmatic About Growth, Will Hawk Mr. Mucus Overseas in 2007
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics plans to expand into international sales through partnerships in fiscal 2007, according to an Aug. 24 analysts call
You may also be interested in...
Reckitt Benckiser Looks Overseas To Double Adams’ Revenue
Reckitt Benckiser should meet its goal of doubling Adams Respiratory Therapeutics' revenues by launching the firms' OTC cough and congestion products overseas and introducing new products being developed by Adams in the United States, analysts and Reckitt executives say
Adams Expands OTC Cough Market Presence With Delsym Acquisition
Adams Respiratory Therapeutics intends to aggressively promote Delsym cough suppressant to consumers following its May 24 acquisition of the brand
Adams Develops New Guaifenesin Products As Mucinex Growth Continues
Adams Respiratory Therapeutics will file an NDA before the end of the year for a product combining the firm's 12-hour extended-release guaifenesin with another respiratory ingredient to create a new, patented combination drug